No Data
No Data
Mural Oncology Initiated at Buy by Rodman & Renshaw
Mural Oncology Initiated at Buy by Rodman & Renshaw
Express News | Rodman & Renshaw Initiates Coverage On Mural Oncology With Buy Rating, Announces Price Target of $15
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to
Express News | Mural Oncology Shares Data From ARTISTRY-3 Trial Designed To Evaluate Effects Of Less Frequent Intravenous Dosing Of Nemvaleukin Alfa In Advance Of ASCO Annual Meeting
Mural Oncology Presents Clinical Data From ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural's late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3 and was generally
Mural Oncology | 10-Q: Quarterly report
No Data